Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116

Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437

A bivalent chromatin structure marks key developmental genes in embryonic stem cells

Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361

Search-and-replace genome editing without double-strand breaks or donor DNA

Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1711-4 · Cited by 4,767

Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage

Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184

CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes

Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696

LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1

Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587

High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells

Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292

Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation

Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.029 · Cited by 2,728

In vivo genome editing using Staphylococcus aureus Cas9

Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687

CRISPR technology: A decade of genome editing is only the beginning

Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,105

Off-target effects in CRISPR/Cas9 gene editing

Guo, C., Ma, X., Gao, F., & Guo, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1143157 · Cited by 704

Therapeutic in vivo delivery of gene editing agents

Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 552

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 506

Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo

An, M., Raguram, A., Du, S. W., Banskota, S., Davis, J. R., Newby, G. A., Chen, P., Palczewski, K., & Liu, D. R. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02078-y · Cited by 275

Comprehensive review of CRISPR-based gene editing: Mechanisms, challenges, and applications in cancer therapy

Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01925-5 · Cited by 251

Prime editing: advances and therapeutic applications

Zhao, Z., Shang, P., Mohanraju, P., & Geijsen, N. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.03.004 · Cited by 205

Nucleic acid drugs: recent progress and future perspectives

Sun, X., Setrerrahmane, S., Li, C., Hu, J., & Xu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02035-4 · Cited by 225

Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives

Souto, E. B., Blanco-Llamero, C., Krambeck, K., Kiran, N. S., Yashaswini, C., Postwala, H. I., Severino, P. B., Priefer, R., Prajapati, B. G., & Maheshwari, R. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.04.010 · Cited by 184

Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery

Aljabali, A. A. A., El‐Tanani, M., & Tambuwala, M. M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105338 · Cited by 186

Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation

Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 153

Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR–Cas gene editing

Zhao, Y., Qin, J., Yu, D., Liu, Y., Song, D., Tian, K., Chen, H., Ye, Q., Wang, X., Xuan, H., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01769-0 · Cited by 126

Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells

Hunt, J., Samson, C., du Rand, A., & Sheppard, H. M. (2023) · Human Genetics · doi:10.1007/s00439-023-02561-1 · Cited by 141

Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines

Nakamura, T., Sato, Y., Yamada, Y., Abd Elwakil, M. M., Kimura, S., Younis, M. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114417 · Cited by 121

Viral and non-viral vectors in gene therapy: current state and clinical perspectives

Geng, G., Xu, Y., Hu, Z., Wang, H., Chen, X., Yuan, W., & Shu, Y. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105834 · Cited by 134

Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy

Dubey, A. K., & Mostafavi, E. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1259435 · Cited by 96

Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy

Zhao, M., Cheng, X., Shao, P., Yao, D., Wu, Y., Xiao, L., Cui, Z., Sun, X., Gao, C., Chen, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44941-9 · Cited by 92

Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications

Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J. K., Gohil, J., Chu, D., Vu‐Thi, H., Alzahrani, K. J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.005 · Cited by 84

Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities

Isazadeh, H., Oruji, F., Shabani, S., Behroozi, J., Nasiri, H., Isazadeh, A., & Akbari, M. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08749-y · Cited by 74

Role of CRISPR-Cas systems and anti-CRISPR proteins in bacterial antibiotic resistance

Kadkhoda, H., Gholizadeh, P., Kafil, H. S., Ghotaslou, R., Pirzadeh, T., Rezaee, M. A., Nabizadeh, E., Feizi, H., & Aghazadeh, M. H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34692 · Cited by 66

The CRISPR/Cas9 System Delivered by Extracellular Vesicles

Zhu, X., Gao, M., Yang, Y., Li, W., Bao, J., & Li, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030984 · Cited by 61

Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing

Fang, T., Cao, X., Ibnat, M., & Chen, G. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01570-y · Cited by 63

Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy

Dou, Y., Chen, R., Liu, S., Lee, Y., Ji, J., Liu, X., Ke, Y., Wang, R., Zhou, Y., & Huang, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41164-2 · Cited by 58

Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components

Wu, F., Li, N., Xiao, Y., Palanki, R., Yamagata, H. M., Mitchell, M. J., & Han, X. (2025) · Small Methods · doi:10.1002/smtd.202401632 · Cited by 64

Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease

Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 63

Gene Therapy Strategies Targeting Aging-Related Diseases

Yu, J., Li, T., & Zhu, J. (2022) · Aging and Disease · doi:10.14336/ad.2022.00725 · Cited by 52

Antimicrobial resistance in Salmonella: One Health perspective on global food safety challenges

Kumar, R., Adeyemi, N. O., Chattaraj, S., Alloun, W., Thamarsha, A. K. A. N. W. M. R. K., Andjelković, S., Mitra, D., & Gautam, P. (2025) · Science in One Health · doi:10.1016/j.soh.2025.100117 · Cited by 50

Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review

Silva, D. F., Melo, A. L. P., Uchôa, A. F. C., Pereira, G. M. A., Alves, Á. E. F., Vasconcellos, M. C., Júnior, F. H. X., & Passos, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316719 · Cited by 53

CRISPR/Cas systems accelerating the development of aptasensors

Zhu, C., Zhang, F., Li, H., Chen, Z., Yan, M., Li, L., & Qu, F. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116775 · Cited by 49

CRISPR delivery with extracellular vesicles: Promises and challenges

Berggreen, A. H., Petersen, J. L., Lin, L., Benabdellah, K., & Luo, Y. (2023) · Journal of Extracellular Biology · doi:10.1002/jex2.111 · Cited by 48

Extracellular Vesicles: The Next Generation of Biomarkers and Treatment for Central Nervous System Diseases

Zanirati, G., dos Santos, P. G., Alcará, A. M., Bruzzo, F. T. K., Ghilardi, I. M., Wietholter, V., Xavier, F. A. C., Gonçalves, J. I. B., Marinowic, D. R., Shetty, A. K., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137371 · Cited by 49

Designing electrospun fiber platforms for efficient delivery of genetic material and genome editing tools

Puhl, D. L., Mohanraj, D., Nelson, D. W., & Gilbert, R. J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114161 · Cited by 46

Oral Microto-Nano Genome-Editing System Enabling Targeted Delivery and Conditional Activation of CRISPR-Cas9 for Gene Therapy of Inflammatory Bowel Disease

Lin, S., Han, S., Wang, X., Wang, X., Shi, X., He, Z., Sun, M., & Sun, J. (2024) · ACS Nano · doi:10.1021/acsnano.4c07750 · Cited by 46

Deciphering the recent trends in pesticide bioremediation using genome editing and multi-omics approaches: a review

Hassan, S., & Ganai, B. A. (2023) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-023-03603-6 · Cited by 45

Genetically engineered hypoimmunogenic cell therapy

Hotta, A., Schrepfer, S., & Nagy, A. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00219-9 · Cited by 44

Study of tree shrew biology and models: A booming and prosperous field for biomedical research

Yao, Y., Lü, L., Ni, R., Bi, R., Chen, C., Chen, J., Fuchs, E., Gorbatyuk, M., Lei, H., Li, H., et al. (2024) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2024.199 · Cited by 41

Recent applications, future perspectives, and limitations of the CRISPR-Cas system

Park, S.-J., Lee, G. E., Cho, S. M., & Choi, E.-H. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102634 · Cited by 45

CRISPR/Cas9-based gene-editing technology for sickle cell disease

Ma, L., Yang, S., Peng, Q., Zhang, J., & Zhang, J. (2023) · Gene · doi:10.1016/j.gene.2023.147480 · Cited by 45

Advancing Therapeutic Strategies with Polymeric Drug Conjugates for Nucleic Acid Delivery and Treatment

Ullah, A., Khan, M., Zhang, Y., Shafiq, M., Ullah, M., Abbas, A., Xianxiang, X., Chen, G., & Diao, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s429279 · Cited by 42

In Vivo Prime Editing by Lipid Nanoparticle Co-Delivery of Chemically Modified pegRNA and Prime Editor mRNA

Chen, Z., Kelly, K., Cheng, H., Dong, X., Hedger, A. K., Li, L., Sontheimer, E. J., & Watts, J. K. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0045 · Cited by 37

Modern therapies of nonsmall cell lung cancer

Jachowski, A., Marcinkowski, M., Szydłowski, J., Grabarczyk, O., Nogaj, Z., Marcin, L. P., Pławski, A., Jagodziński, P. P., & Słowikowski, B. K. (2023) · Journal of Applied Genetics · doi:10.1007/s13353-023-00786-4 · Cited by 36

Optimizing CRISPR/Cas9 precision: Mitigating off-target effects for safe integration with photodynamic and stem cell therapies in cancer treatment

Merlin, J. P. J., & Abrahamse, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117516 · Cited by 35

Advancements in CRISPR/Cas systems for disease treatment

Xu, Y., Le, H., Wu, Q., Wang, N., & Gong, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.007 · Cited by 35

Bubble-Based Drug Delivery Systems: Next-Generation Diagnosis to Therapy

Kancheva, M., Aronson, L., Pattilachan, T. M., Sautto, F., Daines, B. S., Thommes, D., Shar, A., & Razavi, M. (2023) · Journal of Functional Biomaterials · doi:10.3390/jfb14070373 · Cited by 34

Gene editing for dyslipidemias: New tools to “cut” lipids

Stankov, S. G., & Cuchel, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.010 · Cited by 34

Nanomaterials for Targeting Liver Disease: Research Progress and Future Perspectives

Wu, Y., Zhang, J. J., He, W., Li, C., & Wang, Y. (2023) · Nano Biomedicine and Engineering · doi:10.26599/nbe.2023.9290024 · Cited by 34

Nanodevices for the Efficient Codelivery of CRISPR-Cas9 Editing Machinery and an Entrapped Cargo: A Proposal for Dual Anti-Inflammatory Therapy

García‐Fernández, A., Vivo‐Llorca, G., Sancho, M., García-Jareño, A. B., Ramírez‐Jiménez, L., Barber‐Cano, E., Murguía, J. R., Orzáez, M., Sancenón, F., & Martínez‐Máñez, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071495 · Cited by 31

Rational Design of Virus-like Particles for Nanomedicine

Shan, W., Wang, C., Chen, H., & Ren, L. (2023) · Accounts of Materials Research · doi:10.1021/accountsmr.3c00050 · Cited by 30

Breaking genetic shackles: The advance of base editing in genetic disorder treatment

Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 32

The potential of gene editing for Huntington’s disease

Duan, W., Urani, E., & Mattson, M. P. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.02.005 · Cited by 31

Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment

Li, M., Chen, F., Yang, Q., Tang, Q., Xiao, Z., Tong, X., Zhang, Y., Lei, L., & Li, S. (2024) · Biomaterials Research · doi:10.34133/bmr.0023 · Cited by 32

Enhanced CRISPR-Cas9 RNA system delivery using cell penetrating peptides-based nanoparticles for efficient in vitro and in vivo applications

Gonzalez, V. G., Grunenberger, A., Nicoud, O., Czuba, E., Vollaire, J., Josserand, V., Guével, X. L., Desai, N., Coll, J., Divita, G., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.008 · Cited by 29

CRISPR/Cas9-Based therapeutics as a promising strategy for management of Alzheimer’s disease: progress and prospects

Khan, M. S., Qureshi, N., Khan, R., Son, Y., & Maqbool, T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1578138 · Cited by 37

Creating superior lungs for transplantation with next-generation gene therapy during ex vivo lung perfusion

Nykänen, A. I., Keshavjee, S. H., & Liu, M. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.01.016 · Cited by 30

Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases

Lei, L., Pan, W., Shou, X., Shao, Y., Ye, S., Zhang, J., Kolliputi, N., & Shi, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02627-w · Cited by 32

Overcoming Photothermal Resistance of Gastric Cancer by Bionic 2D Iron-Based Nanoplatforms with Precise CRISPR/Cas9 Delivery

Liu, H., Yang, Y., Zhang, N., Hou, Y., Zhang, Z., Yu, X., Huang, Y., Yan, B., Zhou, H., Mu, M., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16846 · Cited by 27

Clinical and Translational Landscape of Viral Gene Therapies

Yudaeva, A., Kostyusheva, A., Kachanov, A., Brezgin, S., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 30

Current Landscape and Emerging Opportunities of Gene Therapy with Non-viral Episomal Vectors

Khan, S. U., Khan, M. U., Khan, M. I., Kalsoom, F., & Zahra, A. (2022) · Current Gene Therapy · doi:10.2174/1566523222666221004100858 · Cited by 26

Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing

Rostami, N., Gomari, M. M., Choupani, E., Abkhiz, S., Fadaie, M., Eslami, S. S., Mahmoudi, Z., Zhang, Y., Puri, M., Monfared, F. N., et al. (2024) · Small Science · doi:10.1002/smsc.202400192 · Cited by 27

Oncolytic viral therapy for gliomas: Advances in the mechanisms and approaches to delivery

Romanishin, A. O., Vasilev, A., Khasanshin, E., Evtekhov, A., Pusynin, E., Rubina, K., Kakotkin, V., Agapov, M., & Semina, E. (2024) · Virology · doi:10.1016/j.virol.2024.110033 · Cited by 24

In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia

Lee, J. H., & Han, J. P. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00705-1 · Cited by 24

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

Hussen, B. M., Najmadden, Z. B., Abdullah, S. R., Rasul, M. F., Mustafa, S. A., Ghafouri‐Fard, S., & Taheri, M. N. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01713-8 · Cited by 28

Genetic improvement in edible fish: status, constraints, and prospects on CRISPR-based genome engineering

Puthumana, J., Chandrababu, A., Sarasan, M., Joseph, V., & Singh, I. S. B. (2024) · 3 Biotech · doi:10.1007/s13205-023-03891-7 · Cited by 24

In vivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular disease

Khirallah, J., Bloomer, H., Wich, D., Huang, C., Workman, J. N., Li, Y., Newby, G. A., Liu, D. R., & Xu, Q. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102486 · Cited by 27

Future Directions for Adrenal Insufficiency: Cellular Transplantation and Genetic Therapies

Graves, L. E., Torpy, D. J., Coates, P. T., Alexander, I. E., Bornstein, S. R., & Clarke, B. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac751 · Cited by 23

Applications of Gene Editing and Nanotechnology in Stem Cell-Based Therapies for Human Diseases

Bolideei, M., Barzigar, R., Gahrouei, R. B., Mohebbi, E., Haider, K. H., Paul, S., Paul, M. K., & Mehran, M. J. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10857-0 · Cited by 22

Metal-phenolic network-based polymeric nanocarriers facilitating antibody cytoplasmic delivery and anti-tumor effects to orthotopic breast tumors

Honda, Y., Haraguchi, H., Tsuda, T., Ko, R., Muguruma, K., Guo, H., Nomoto, T., Miura, Y., & Nishiyama, N. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113929 · Cited by 20

Differences and Similarities of the Intravenously Administered Lipid Nanoparticles in Three Clinical Trials: Potential Linkage between Lipid Nanoparticles and Extracellular Vesicles

Suzuki, Y., Katsurada, Y., & Hyodo, K. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00547 · Cited by 23

Functionalized extracellular nanovesicles as advanced CRISPR delivery systems

Wang, S., Kong, H., Zhuo, C., Liu, L., Lv, S., Cheng, D., Lao, Y., Tao, Y., & Li, M. (2024) · Biomaterials Science · doi:10.1039/d4bm00054d · Cited by 22

Therapeutic applications of nanobots and nanocarriers in cancer treatment

Khan, Z., Khan, N., Geetha, M., Veettil, R. P., Kasote, D. M., Hasan, A., & Sadasivuni, K. K. (2025) · Analytical Sciences · doi:10.1007/s44211-025-00799-5 · Cited by 24

Genome editing in cancer: Challenges and potential opportunities

Breier, D., & Peer, D. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.08.013 · Cited by 21

Noncoding RNAs : Emerging regulators of behavioral complexity

Dayal, S., Chaubey, D., Joshi, D. C., Ranmale, S., & Pillai, B. (2024) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1847 · Cited by 22

Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma

Zhang, Y., Rabinovsky, R., Deforzh, E., Kobayashi, A., Kuzkina, A., Varghese, J. F., Rai, D., Korecka, J. A., Khurana, V., Murugaiyan, G., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf162 · Cited by 18

Emerging trends in virus and virus-like particle gene therapy delivery to the brain

Mandalawatta, H. P. P., Rajendra, K. C., Fairfax, K. A., & Hewitt, A. W. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102280 · Cited by 18

Use of gene therapy for optic nerve protection: Current concepts

Xu, K., Yu, L., Wang, Z., Lin, P., Zhang, N., Xing, Y., & Yang, N. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1158030 · Cited by 19

Development of New Genome Editing Tools for the Treatment of Hyperlipidemia

Preta, G. (2023) · Cells · doi:10.3390/cells12202466 · Cited by 19

Natural Biopolymer-Based Delivery of CRISPR/Cas9 for Cancer Treatment

Lin, M., & Wang, X. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010062 · Cited by 18

Efficient non-viral delivery of macromolecules in human primary hematopoietic stem cells and lymphocytes

Chuan-ping, Z., Qiu, H.-Y., Zhang, C., Zhang, Y., Zhang, Y., Yin, H., Zhang, K., & Zhang, Y. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad018 · Cited by 16

CRISPR/Cas9 as a Mutagenic Factor

Shumega, A. R., Pavlov, Y. I., Chirinskaite, A. V., Rubel, A. A., Inge-Vechtomov, S. G., & Stepchenkova, E. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020823 · Cited by 18

CRISPR/Cas: History and Perspectives

Shmakova, A., Shmakova, O. P., Karpukhina, A. A., & Vassetzky, Y. S. (2022) · Russian Journal of Developmental Biology · doi:10.1134/s1062360422040075 · Cited by 17

CRISPR delivery systems for organ-specific targeting: Advances and challenges

Du, J., Wu, Q., Liu, C., Wang, N., & Gong, C. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100048 · Cited by 20

Delivery challenges for CRISPR—Cas9 genome editing for Duchenne muscular dystrophy

Padmaswari, M. H., Agrawal, S., Jia, M. S., Ivy, A., Maxenberger, D. A., Burcham, L. A., & Nelson, C. E. (2023) · Biophysics Reviews · doi:10.1063/5.0131452 · Cited by 18

Split dCas12a activator for lncRNA H19 activation to enhance BMSC differentiation and promote calvarial bone healing

Nguyen, N. T. K., Tu, Y., Lee, H.-S., Truong, V. A., Chang, Y., Pham, N. N., Chang, C.-W., Lin, Y.-H., Lai, P.-L., Chen, P., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122106 · Cited by 17

Gene Therapy: Towards a New Era of Medicine

Bhagat, M., Kamal, R., Sharma, J., Kaur, K., Sharma, A. K., Singh, T. G., Bhatia, R., & Awasthi, A. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-03010-6 · Cited by 16

RYR-1-Related Diseases International Research Workshop: From Mechanisms to Treatments Pittsburgh, PA, U.S.A., 21-22 July 2022

O’Connor, T. N., van den Bersselaar, L. R., Chen, Y. S., Nicolau, S., Simon, B., Huseth, A., Todd, J. J., Petegem, F. V., Sárközy, A., Goldberg, M. F., et al. (2022) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-221609 · Cited by 15

Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy

Piccolo, P., & Brunetti‐Pierri, N. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.179 · Cited by 15

BSA-PEI Nanoparticle Mediated Efficient Delivery of CRISPR/Cas9 into MDA-MB-231 Cells

Rahimi, H., Zaboli, K. A., Thekkiniath, J., Mousavi, S. H., Johari, B., Hashemi, M. R., Nosrati, H., Goldschneider, D., Bernet, A., Danafar, H., et al. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00514-z · Cited by 14

Role of CRISPR/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies

Agrawal, P., Harish, V., Mohd, S., Singh, S. K., Tewari, D., Tatiparthi, R., Harshita, Vishwas, S., Sutrapu, S., Dua, K., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122003 · Cited by 17

Advances in liposome-based delivery of RNA therapeutics for cancer treatment

Sanati, M., Afshari, A. R., Ahmadi, S. S., Kesharwani, P., & Sahebkar, A. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.010 · Cited by 14

Non-Viral CRISPR carriers: transient delivery with lasting effects

Lummerstorfer, M., & Lächelt, U. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2614125 · Cited by 14

Genetic therapies and potential therapeutic applications of CRISPR activators in the eye

Ng, B., Kaukonen, M. K., McClements, M. E., Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101289 · Cited by 13

Nanotechnology and CRISPR/Cas-Mediated Gene Therapy Strategies: Potential Role for Treating Genetic Disorders

Kaur, G., Arora, J., Sodhi, A. S., Bhatia, S., & Batra, N. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01301-8 · Cited by 14

Prime Editing: The Next Frontier in Precision Gene Therapy

Aliciaslan, M., Erbasan, E., Erendor, F., & Şanlıoğlu, S. (2025) · The Journal of Gene Medicine · doi:10.1002/jgm.70040 · Cited by 13

Navigating the CRISPR/Cas Landscape for Enhanced Diagnosis and Treatment of Wilson’s Disease

Choi, W., Cha, S., & Kim, K. (2024) · Cells · doi:10.3390/cells13141214 · Cited by 15

Vectors in CRISPR Gene Editing for Neurological Disorders: Challenges and Opportunities

Xiong, K., Wang, X., Feng, C., Zhang, K., Chen, D., & Yang, S. (2025) · Advanced Biology · doi:10.1002/adbi.202400374 · Cited by 12

Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells

Sahu, S. U., Castro, M., Muldoon, J. J., Asija, K., Wyman, S. K., Krishnappa, N., de Oñate, L., Eyquem, J., Nguyen, D. N., & Wilson, R. C. (2025) · Nature Protocols · doi:10.1038/s41596-025-01154-8 · Cited by 19

Current and emerging therapies for endometriosis-associated pain: a review

Tijani, E. O., Ajayi, L. O., Tijani, O. S., Akano, O. P., & Ajayi, A. F. (2025) · Middle East Fertility Society Journal · doi:10.1186/s43043-025-00221-0 · Cited by 14

Nanotechnology in Gene Editing: Pioneering CRISPR‐Cas Delivery Systems to Tackle Antibiotic Resistance

Gholamian, S., Baghaee, P., & Doroudian, M. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202400412 · Cited by 15

The history, use, and challenges of therapeutic somatic cell and germline gene editing

Ryu, J., Adashi, E. Y., & Hennebold, J. D. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.02.040 · Cited by 12

Liposome‐Enabled Nanomaterials for Muscle Regeneration

Wu, S., & Lu, J. (2025) · Small Methods · doi:10.1002/smtd.202402154 · Cited by 11

Engineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing

Moyo, B., Brown, L. B. C., Khondaker, I., & Bao, G. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123314 · Cited by 13

In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease

Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161

Drug delivery systems for CRISPR-based genome editors

Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 193

Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors

Rice-Boucher, P. J., Cui, X., & Curiel, D. T. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.003 · Cited by 62

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives

Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 3